195. Noonan syndrome
14 clinical trials,   15 drugs   (DrugBank: 5 drugs),   2 drug target genes,   9 drug target pathways

Searched query = "Noonan syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03435627
(ClinicalTrials.gov)
February 26, 201831/1/2018Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)Genetic Disorder;Noonan SyndromeDrug: SomatropinNovo Nordisk A/SNULLActive, not recruiting3 YearsN/AAll60Japan
2NCT01927861
(ClinicalTrials.gov)
August 19, 201320/8/2013Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan SyndromeA 52-week, Multi-centre, Randomised, Double-blind, Parallel-group, no Treatment Controlled (Open-label) Trial Investigating the Efficacy and Safety of Two Doses of NN-220 in Short Stature With Noonan SyndromeGenetic Disorder;Noonan SyndromeDrug: somatropinNovo Nordisk A/SNULLCompleted3 Years10 YearsAll51Phase 3Japan
3NCT01529944
(ClinicalTrials.gov)
September 20082/1/2012Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658Genetic Testing of Noonan Subjects Previously Treated With Norditropin® in the GHNOO-1658 TrialGenetic Disorder;Noonan SyndromeDrug: somatropinNovo Nordisk A/SNULLCompletedN/AN/ABoth22Phase 3Sweden
4NCT00960128
(ClinicalTrials.gov)
April 1, 200613/8/2009Observational Prospective Study on Patients Treated With Norditropin®NordiNet® International Outcome Study-Observational Prospective Study on Patients Treated With Norditropin®Growth Hormone Disorder;Growth Hormone Deficiency in Children;Adult Growth Hormone Deficiency;Genetic Disorder;Turner Syndrome;Foetal Growth Problem;Small for Gestational Age;Chronic Kidney Disease;Chronic Renal Insufficiency;Noonan SyndromeDrug: somatropinNovo Nordisk A/SNULLCompletedN/AN/AAll21249N/AArgentina;Belgium;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Lithuania;Luxembourg;Netherlands;Norway;Russian Federation;Saudi Arabia;Serbia;Slovenia;Spain;Sweden;Switzerland;United Kingdom;Brazil;Czech Republic;Former Serbia and Montenegro
5EUCTR2005-000042-37-SE
(EUCTR)
11/07/200512/04/2005Norditropin Treatment in Subjects with Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up VisitNorditropin Treatment in Subjects with Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up Visit Noonan syndrome associated short stature
MedDRA version: 7.1;Level: PT;Classification code 10029748
Trade Name: Norditropin 24 IU
Product Name: Norditropin 24 IU
INN or Proposed INN: Somatropin
Trade Name: Norditropin SimpleXx
Product Name: Norditropin SimpleXx
INN or Proposed INN: Somatropin
INN or Proposed INN: Somatropin
INN or Proposed INN: Somatropin
Novo Nordisk A/SNULLNot RecruitingFemale: yes
Male: yes
Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01529840
(ClinicalTrials.gov)
June 19902/1/2012Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan SyndromeNorditropin Treatment in Subjects With Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up VisitGenetic Disorder;Noonan SyndromeDrug: somatropinNovo Nordisk A/SNULLCompleted18 YearsN/AAll24Phase 3Sweden